Project description DEENESFRITPL Unique facial filler for a younger look Some people hope to grow old gracefully, while others are looking for anti-ageing treatments. Cosmetic facial injections are becoming increasingly popular. However, current solutions are not only expensive but also come with side effects – from swelling and redness to bleeding and allergic reactions. In this context, the EU-funded Volumizer project will bring to market a unique anti-ageing treatment that combats facial ageing at the source by increasing local fat tissue in the face for a healthier and younger look. To reach commercialisation, the project will look to execute first in human trials and subsequent clinical trials to validate the efficacy. These results will be used in order to apply for CE marking certifying that the product has met the EU health, safety, and environmental requirements. Show the project objective Hide the project objective Objective Aging is something that affects everyone. In order to combat the effects of aging, in a time where social and aesthetic appeal is so popular, people have turned to aesthetic injectables as a way to look and feel rejuvenated. Unfortunately, there are a multitude of problems with available facial fillers. Current solutions available on the market often have a multitude of side effects such as swelling, redness, bleeding or allergic reactions. Additionally, the procedures are costly, and due to the short term results, will produce a greater economic burden as continuous application is needed. PB&B has developed a unique anti-aging Volumizer that combats facial aging at the source by increasing local fat tissue in the face for a healthier and younger look. The solution is injected directly into the face, where over two months, the solution slowly evenly fills the wrinkles and deep fat tissue compartments. In order to reach commercialization, the Company will look to execute first in human trials and subsequent clinical trials to validate the efficacy. These results will be used in order to apply for CE certification. During the Phase 1 feasibility assessment PB&B will need to define a target segment of users within the markets of aesthetic products and facial injectables. A scaled up supply chain will need to be established in order to optimize distribution and market demand. Intellectual property will need to be patented after research and development has produced a product for commercialization. Fields of science medical and health sciencesclinical medicinesurgerysocial scienceseconomics and businessbusiness and managementbusiness models Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator PB&B SA Net EU contribution € 50 000,00 Address Avenue de gratta-paille 2 1018 Lausanne Switzerland See on map Region Schweiz/Suisse/Svizzera Région lémanique Vaud Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
